Press Releases Replimune Group, Inc.

Equities

REPL

US76029N1063

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
6.41 ^USD	-4.75%		-7.77%	-23.96%

08/04	Replimune Group Provides Interim Results for Skin Cancer Therapy	MT
26/03	Replimune Group, Inc. Announces Management Changes	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Replimune : Corporate Presentation May 2024	08/05	PU
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting	08/04	AQ
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/04	AQ
Replimune : Uveal Melanoma Biomarker Poster at AACR 2024	01/04	PU
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions	26/03	AQ
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024	06/03	AQ
Replimune to Present at Three Upcoming Investor Conferences	05/03	AQ
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update	08/02	AQ
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference	28/12	AQ
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers	05/12	AQ
Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research	08/11	AQ
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update	07/11	AQ
Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)	04/11	AQ
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20/23/20	AQ
Replimune Announces Appointment of Emily Hill as Chief Financial Officer	19/23/19	AQ
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya's Board of Directors	22/23/22	AQ
Replimune : Corporate Presentation August 2023	11/23/11	PU
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update	03/23/03	AQ
Replimune to Present at Two Upcoming Investor Conferences	01/23/01	AQ
Replimune Announces Sander Slootweg will Depart from its Board of Directors	20/23/20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Replimune Group, Inc.

Equities

REPL

US76029N1063

Press Releases

Filters